Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
The present study investigates the applicability of nanoparticle delivery vectors for two-stage targeting that involves both cell entry by endocytosis and nuclear targeting using viral peptide signals. A nanoparticle vector consists of four components: a carrier nanoparticle, a stabilizer, targeting peptides, and a therapeutic cargo. Extensive study of bovine serum albumin (BSA)-peptide stabilized nanoparticle conjugates demonstrated limitations of these systems due to colloidal instability when oligonucleotides and multiple peptides were attached to the BSA protein. We found that the widely used protein streptavidin (SA) was an appropriate alternative to BSA for cell-targeting experiments. Targeting peptides and gene splicing oligonucleotides were attached to SA-nanoparticles using biotin labels. The present study uses a gene-splicing assay as a test for oligonucleotide delivery to the cell nucleus. Successful modification of gene splicing by an antisense oligonucleotide indicates that the latter must have crossed the plasma membrane, entered the nucleus, found the target sequence in the newly transcribed pre-mRNA, and hybridized to it in the spliceosome strongly enough to displace the splicing factors designed to interact with the target sequence. Targeting nanoparticles that carry gene-splicing oligonucleotides were compared with a control experiment that used lipofectamine (LF). While enhanced activity was observed in the control experiment, in the presence of LF, no gene splicing was observed for the nanoparticle targeting vectors without LF. We conclude that sequestration of cargo from the harsh conditions of the endosome is a desirable strategy for cell-targeting nanoparticles.
Liu
Yanli
Y
Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, USA.
Franzen
Stefan
S
D017398:Alternative Splicing; D019921:Biotinylation; D002467:Cell Nucleus / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D003102:Colloids / Q000737:chemistry; D004705:Endocytosis / Q000187:drug effects; D011992:Endosomes / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D005822:Genetic Vectors / Q000737:chemistry* / Q000378:metabolism; D006046:Gold / Q000737:chemistry* / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D008055:Lipids / Q000737:chemistry / Q000494:pharmacology; D053768:Metal Nanoparticles / Q000737:chemistry*; D016376:Oligonucleotides, Antisense / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics; D012710:Serum Albumin, Bovine / Q000737:chemistry / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000737:chemistry; D013873:Thionucleotides / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D017086:beta-Thalassemia / Q000235:genetics
D003102:Colloids; D008055:Lipids; C086724:Lipofectamine; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D013438:Sulfhydryl Compounds; D013873:Thionucleotides; D012710:Serum Albumin, Bovine; D006046:Gold